Literature DB >> 28979182

Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing.

Angelo Corti1, Anna Maria Gasparri2, Michela Ghitti2, Angelina Sacchi1, Francesco Sudati2, Martina Fiocchi2, Valentina Buttiglione2, Laura Perani2, Alessandro Gori3, Silvia Valtorta2,4, Rosa Maria Moresco2,4, Fabio Pastorino5, Mirco Ponzoni5, Giovanna Musco2, Flavio Curnis2.   

Abstract

NGR (asparagine-glycine-arginine) is a tumor vasculature-homing peptide motif widely used for the functionalization of drugs, nanomaterials and imaging compounds for cancer treatment and diagnosis. Unfortunately, this motif has a strong propensity to undergo rapid deamidation. This reaction, which converts NGR into isoDGR, is associated with receptor switching from CD13 to integrins, with potentially important manufacturing, pharmacological and toxicological implications. It is found that glycine N-methylation of NGR-tagged nanocarriers completely prevents asparagine deamidation without impairing CD13 recognition. Studies in animal models have shown that the methylated NGR motif can be exploited for delivering radiolabeled compounds and nanocarriers, such as tumor necrosis factor-α (TNF)-bearing nanogold and liposomal doxorubicin, to tumors with improved selectivity. These findings suggest that this NGR derivative is a stable and efficient tumor-homing ligand that can be used for delivering functional nanomaterials to tumor vasculature.

Entities:  

Keywords:  N-methylglycine; deamidation; enzyme; molecular docking; peptides

Year:  2017        PMID: 28979182      PMCID: PMC5624507          DOI: 10.1002/adfm.201701245

Source DB:  PubMed          Journal:  Adv Funct Mater        ISSN: 1616-301X            Impact factor:   18.808


  34 in total

1.  Protein deamidation.

Authors:  Noah E Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

2.  Conformational control of integrin-subtype selectivity in isoDGR peptide motifs: a biological switch.

Authors:  Andreas O Frank; Elke Otto; Carlos Mas-Moruno; Herbert B Schiller; Luciana Marinelli; Sandro Cosconati; Alexander Bochen; Dörte Vossmeyer; Grit Zahn; Roland Stragies; Ettore Novellino; Horst Kessler
Journal:  Angew Chem Int Ed Engl       Date:  2010-11-22       Impact factor: 15.336

3.  Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancer.

Authors:  T C Stam; M Jongen-Lavrencic; A M Eggermont; A J Swaak
Journal:  Eur J Clin Invest       Date:  1996-12       Impact factor: 4.686

4.  CD13/APN is activated by angiogenic signals and is essential for capillary tube formation.

Authors:  S V Bhagwat; J Lahdenranta; R Giordano; W Arap; R Pasqualini; L H Shapiro
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

5.  Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes α5β1 and αvβ6: conformational control through flanking amino acids.

Authors:  Alexander Bochen; Udaya Kiran Marelli; Elke Otto; Diego Pallarola; Carlos Mas-Moruno; Francesco Saverio Di Leva; Heike Boehm; Joachim P Spatz; Ettore Novellino; Horst Kessler; Luciana Marinelli
Journal:  J Med Chem       Date:  2013-02-18       Impact factor: 7.446

6.  Spontaneous formation of L-isoaspartate and gain of function in fibronectin.

Authors:  Flavio Curnis; Renato Longhi; Luca Crippa; Angela Cattaneo; Eleonora Dondossola; Angela Bachi; Angelo Corti
Journal:  J Biol Chem       Date:  2006-10-02       Impact factor: 5.157

7.  IsoDGR-tagged albumin: a new αvβ3 selective carrier for nanodrug delivery to tumors.

Authors:  Flavio Curnis; Angelina Sacchi; Renato Longhi; Barbara Colombo; Anna Gasparri; Angelo Corti
Journal:  Small       Date:  2012-11-12       Impact factor: 13.281

8.  Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.

Authors:  Flavio Curnis; Gianluigi Arrigoni; Angelina Sacchi; Lucia Fischetti; Wadih Arap; Renata Pasqualini; Angelo Corti
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

9.  Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.

Authors:  Vanesa Gregorc; Giovanni Citterio; Giordano Vitali; Anna Spreafico; Paola Scifo; Anna Borri; Giovanni Donadoni; Gilda Rossoni; Angelo Corti; Federico Caligaris-Cappio; Alessandro Del Maschio; Antonio Esposito; Francesco De Cobelli; Flavio Dell'Acqua; Antonella Troysi; Paolo Bruzzi; Antonio Lambiase; Claudio Bordignon
Journal:  Eur J Cancer       Date:  2010-01       Impact factor: 9.162

10.  A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins.

Authors:  Tobias G Kapp; Florian Rechenmacher; Stefanie Neubauer; Oleg V Maltsev; Elisabetta A Cavalcanti-Adam; Revital Zarka; Ute Reuning; Johannes Notni; Hans-Jürgen Wester; Carlos Mas-Moruno; Joachim Spatz; Benjamin Geiger; Horst Kessler
Journal:  Sci Rep       Date:  2017-01-11       Impact factor: 4.379

View more
  3 in total

1.  Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR/cytokine-coated nanogold.

Authors:  Angelo Corti; Angelina Sacchi; Anna Maria Gasparri; Matteo Monieri; Giulia Anderluzzi; Barbara Colombo; Alessandro Gori; Anna Mondino; Flavio Curnis
Journal:  J Nanobiotechnology       Date:  2021-05-05       Impact factor: 10.435

Review 2.  Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor-α.

Authors:  Angelo Corti; Teresa Calimeri; Flavio Curnis; Andres J M Ferreri
Journal:  Pharmaceutics       Date:  2022-07-06       Impact factor: 6.525

Review 3.  Molecular Imaging of Aminopeptidase N in Cancer and Angiogenesis.

Authors:  Cynthia L Schreiber; Bradley D Smith
Journal:  Contrast Media Mol Imaging       Date:  2018-06-25       Impact factor: 3.161

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.